FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3007665819> ?p ?o ?g. }

• W3007665819 endingPage "2545" @default.
• W3007665819 startingPage "2535" @default.
• W3007665819 abstract "Abstract Purpose: Most ALK-positive lung cancers will develop ALK-independent resistance after treatment with next-generation ALK inhibitors. MET amplification has been described in patients progressing on ALK inhibitors, but frequency of this event has not been comprehensively assessed. Experimental Design: We performed FISH and/or next-generation sequencing on 207 posttreatment tissue (n = 101) or plasma (n = 106) specimens from patients with ALK-positive lung cancer to detect MET genetic alterations. We evaluated ALK inhibitor sensitivity in cell lines with MET alterations and assessed antitumor activity of ALK/MET blockade in ALK-positive cell lines and 2 patients with MET-driven resistance. Results: MET amplification was detected in 15% of tumor biopsies from patients relapsing on next-generation ALK inhibitors, including 12% and 22% of biopsies from patients progressing on second-generation inhibitors or lorlatinib, respectively. Patients treated with a second-generation ALK inhibitor in the first-line setting were more likely to develop MET amplification than those who had received next-generation ALK inhibitors after crizotinib (P = 0.019). Two tumor specimens harbored an identical ST7-MET rearrangement, one of which had concurrent MET amplification. Expressing ST7-MET in the sensitive H3122 ALK-positive cell line induced resistance to ALK inhibitors that was reversed with dual ALK/MET inhibition. MET inhibition resensitized a patient-derived cell line harboring both ST7-MET and MET amplification to ALK inhibitors. Two patients with ALK-positive lung cancer and acquired MET alterations achieved rapid responses to ALK/MET combination therapy. Conclusions: Treatment with next-generation ALK inhibitors, particularly in the first-line setting, may lead to MET-driven resistance. Patients with acquired MET alterations may derive clinical benefit from therapies that target both ALK and MET." @default.
• W3007665819 created "2020-03-06" @default.
• W3007665819 creator A5000653317 @default.
• W3007665819 creator A5005596596 @default.
• W3007665819 creator A5009049676 @default.
• W3007665819 creator A5009622856 @default.
• W3007665819 creator A5016467233 @default.
• W3007665819 creator A5032331306 @default.
• W3007665819 creator A5033265658 @default.
• W3007665819 creator A5037214933 @default.
• W3007665819 creator A5044838791 @default.
• W3007665819 creator A5048670338 @default.
• W3007665819 creator A5052336062 @default.
• W3007665819 creator A5052578824 @default.
• W3007665819 creator A5060699951 @default.
• W3007665819 creator A5067299042 @default.
• W3007665819 creator A5067755945 @default.
• W3007665819 creator A5070808897 @default.
• W3007665819 creator A5075739031 @default.
• W3007665819 creator A5080311196 @default.
• W3007665819 creator A5081227348 @default.
• W3007665819 creator A5085217465 @default.
• W3007665819 creator A5087906702 @default.
• W3007665819 creator A5088120981 @default.
• W3007665819 creator A5089382639 @default.
• W3007665819 date "2020-06-01" @default.
• W3007665819 modified "2023-10-10" @default.
• W3007665819 title "MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer" @default.
• W3007665819 cites W1969391810 @default.
• W3007665819 cites W1998971866 @default.
• W3007665819 cites W2004202575 @default.
• W3007665819 cites W2055402151 @default.
• W3007665819 cites W2062291041 @default.
• W3007665819 cites W2099530756 @default.
• W3007665819 cites W2154149901 @default.
• W3007665819 cites W2160981405 @default.
• W3007665819 cites W2205646851 @default.
• W3007665819 cites W2212335550 @default.
• W3007665819 cites W2482427906 @default.
• W3007665819 cites W2544185683 @default.
• W3007665819 cites W2581996620 @default.
• W3007665819 cites W2597631157 @default.
• W3007665819 cites W2624310346 @default.
• W3007665819 cites W2767072667 @default.
• W3007665819 cites W2797685139 @default.
• W3007665819 cites W2800224623 @default.
• W3007665819 cites W2802365177 @default.
• W3007665819 cites W2887029617 @default.
• W3007665819 cites W2889373434 @default.
• W3007665819 cites W2894066036 @default.
• W3007665819 cites W2894476389 @default.
• W3007665819 cites W2923683745 @default.
• W3007665819 cites W2927631105 @default.
• W3007665819 cites W2947852198 @default.
• W3007665819 cites W2954565338 @default.
• W3007665819 cites W2978074062 @default.
• W3007665819 doi "https://doi.org/10.1158/1078-0432.ccr-19-3906" @default.
• W3007665819 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7269872" @default.
• W3007665819 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32086345" @default.
• W3007665819 hasPublicationYear "2020" @default.
• W3007665819 type Work @default.
• W3007665819 sameAs 3007665819 @default.
• W3007665819 citedByCount "110" @default.
• W3007665819 countsByYear W30076658192020 @default.
• W3007665819 countsByYear W30076658192021 @default.
• W3007665819 countsByYear W30076658192022 @default.
• W3007665819 countsByYear W30076658192023 @default.
• W3007665819 crossrefType "journal-article" @default.
• W3007665819 hasAuthorship W3007665819A5000653317 @default.
• W3007665819 hasAuthorship W3007665819A5005596596 @default.
• W3007665819 hasAuthorship W3007665819A5009049676 @default.
• W3007665819 hasAuthorship W3007665819A5009622856 @default.
• W3007665819 hasAuthorship W3007665819A5016467233 @default.
• W3007665819 hasAuthorship W3007665819A5032331306 @default.
• W3007665819 hasAuthorship W3007665819A5033265658 @default.
• W3007665819 hasAuthorship W3007665819A5037214933 @default.
• W3007665819 hasAuthorship W3007665819A5044838791 @default.
• W3007665819 hasAuthorship W3007665819A5048670338 @default.
• W3007665819 hasAuthorship W3007665819A5052336062 @default.
• W3007665819 hasAuthorship W3007665819A5052578824 @default.
• W3007665819 hasAuthorship W3007665819A5060699951 @default.
• W3007665819 hasAuthorship W3007665819A5067299042 @default.
• W3007665819 hasAuthorship W3007665819A5067755945 @default.
• W3007665819 hasAuthorship W3007665819A5070808897 @default.
• W3007665819 hasAuthorship W3007665819A5075739031 @default.
• W3007665819 hasAuthorship W3007665819A5080311196 @default.
• W3007665819 hasAuthorship W3007665819A5081227348 @default.
• W3007665819 hasAuthorship W3007665819A5085217465 @default.
• W3007665819 hasAuthorship W3007665819A5087906702 @default.
• W3007665819 hasAuthorship W3007665819A5088120981 @default.
• W3007665819 hasAuthorship W3007665819A5089382639 @default.
• W3007665819 hasBestOaLocation W30076658192 @default.
• W3007665819 hasConcept C117643217 @default.
• W3007665819 hasConcept C121608353 @default.
• W3007665819 hasConcept C126322002 @default.
• W3007665819 hasConcept C143998085 @default.
• W3007665819 hasConcept C2776232967 @default.
• W3007665819 hasConcept C2776256026 @default.

• next